Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection

Clinical Infectious Diseases

Volumn 44, Issue 3, 2007, Pages 456-458

  Smith, Davey ^a,b   Moini, Niousha ^a   Pesano, Rick ^c   Cachay, Edward ^a   Aiem, Heidi ^a   Lie, Yolanda ^c   Richman, Douglas ^a,b   Little, Susan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE DURATION; DISEASE TRANSMISSION; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS M184V; INFECTION RATE; MAJOR CLINICAL STUDY; PHYLOGENY; PRACTICE GUIDELINE; PRIORITY JOURNAL; VIRUS STRAIN;

ANTI-HIV AGENTS; CALIFORNIA; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MALE; PATIENT CARE PLANNING; PREVALENCE; TREATMENT OUTCOME;

EID: 33846440130     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510748     Document Type: Article

References (23)

1. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-94.
2. Little SJ, May S, Hecht F, et al. Increase in transmitted NNRTI drug resistance among recently HIV infected patients from North America and Australia. Antivir Ther 2006; 11:5110.
3. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of anti-retroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189:2174-80.
4. Brooks JI, Pilon RG, Merks HW, et al. Regional variation in HIV strain and drug resistance: the Canadian experience with a national surveillance program. Antivir Ther 2006; 11:S119.
5. Escoto-Delgadillo M, Vazquez-Valls E, Ramirez-Rodriguez M, et al. Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV Med 2005; 6:403-9.
6. Wensing AM, Van De Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-66.
7. Weinstein MC, Goldie SI, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134:440-50.
8. Brenner BG, Routy JP, Petrella M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76:1753-61.
9. Gandhi RT, Wurcel A, Lee H, et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis 2003; 36:1602-5.
10. Barbour JD, Hecht FM, Wrin T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18:1683-9.
11. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113-28.
12. Little SJ, Smith DM. HIV treatment decisions and transmitted drug resistance. Clin Infect Dis 2005; 41:233-5.
13. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 2006; 14:125-30.
14. Olsen GJ, Matsuda H, Hagstrom R, Overbeek R. fastDNAmL: a tool for construction of phylogenetic trees of DNA sequences using maximum likelihood. Comput Appl Biosci 1994; 10:41-8.
15. Hue S, Clewley JP, Cane PA, Pillay D. HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy. AIDS 2004; 18:719-28.
16. Violin M, Cozzi-Lepri A, Velleca R, et al. Risk of failure in patients with 215 HIV-1 revenants starting their first analog-containing highly active antiretroviral therapy. AIDS 2004; 18:227-35.
17. County of San Diego Health and Human Services Agency, HIV/AIDS Epidemiology Unit. AIDS in men who have sex with men. County of San Diego, 2004. Available at: http://www2.sdcounty.ca.gov/hhsa/documents/ AIDS_in_MSM.pdf. Accessed 1 May 2006.
18. Eshleman SH, Husnik M, Hudelson S, et al. Analysis of antiretroviral drug resistance and HIV-1 subtype among men who have sex with men recently infected with HIV-1 in the United States: the EXPLORE Study. Antivir Ther 2006; 11:5122.
19. County of San Diego Health and Human Services Agency, HIV/AIDS Epidemiology Unit. HIV/AIDS Epidemiology Report 2005. County of San Diego, 2005. Available at: http://www2.sdcounty.ca.gov/hhsa/documents/ 2005AnnualReport.pdf. Accessed 20 September 2006.
20. Gallant JE. Antiretroviral drug resistance and resistance testing. Top HIV Med 2005; 13:138-42.
21. Besch CL. Antiretroviral therapy in drug-naive patients infected with human immunodeficiency virus. Am J Med Sci 2004; 328:3-9.
22. Roland ME, Neilands TB, Krone MR, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005; 41:1507-13.
23. Daskalakis D, Bernstein KT, Hagerty R, et al. HIV pre- and post-exposure prophylaxis among bathhouse patrons [late breaker poster 8], In: Program and abstracts of the 5th National STD Prevention Conference (Jacksonville, FL). Atlanta, GA: Centers for Disease Control and Prevention, 2006.